Dr. Reddy’s inks licensing agreement with Slayback for Lumify OTC

Dr. Reddy’s has entered into a licensing agreement with Slayback to acquire rights in the company’s brimonidine tartrate ophthalmic solution 0.025%, the private label equivalent of Lumify, in the United States.

Lumify is an over-the-counter eyedrop that works to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.

Slayback is the first company to file an ANDA for the private label equivalent of Lumify with the FDA under Paragraph IV certification. The ANDA is currently under FDA review and covers Brimonidine Tartrate ophthalmic solution 0.025% in 2.5 ml and 7.5 ml fill volumes.

[Read more: Dr. Reddy's Aurigen Pharmaceutical Services names CEO] 

“We are pleased to license this important OTC ophthalmic product for the U.S. market,” said Marc Kikuchi, CEO of North America generics at Dr. Reddy’s. “This product complements Dr. Reddy’s growing OTC product portfolio in the eye care category that includes the private label versions of Pataday Once Daily Relief and Pataday Twice Daily Relief.”

The product has a market value of roughly $130 million for the 52-week period ending June 12, 2022, according to IRI data.

[Read more: Slayback Pharma gets $50 million investment from The Everstone Group] 

“Slayback is proud to develop this first-to-file ANDA for Lumify, a significant OTC product in the eye redness reliever category, that continues to highlight the R&D capability of the company,” said Ajay Singh, CEO and founder of Slayback.

Pataday Once Daily Relief and Pataday Twice Daily Relief are trademarks of Alcon.